How to buy Seelos Therapeutics stock - 18 April

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Seelos Therapeutics stock

Own Seelos Therapeutics stock in just a few minutes.

Seelos Therapeutics, Inc is a biotechnology business based in the US. Seelos Therapeutics shares (SEEL) are listed on the NASDAQ and all prices are listed in US Dollars. Seelos Therapeutics employs 9 staff and has a market cap (total outstanding shares value) of USD0.00.

How to buy shares in Seelos Therapeutics

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Seelos Therapeutics. Find the stock by name or ticker symbol: SEEL. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Seelos Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Seelos Therapeutics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Seelos Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Seelos Therapeutics share price

Use our graph to track the performance of SEEL stocks over time.

Seelos Therapeutics shares at a glance

Information last updated 2021-04-16.
52-week rangeUSD$0.45 - USD$6.16
50-day moving average USD$4.1791
200-day moving average USD$2.2186
Wall St. target priceUSD$11.75
PE ratio 0.7803
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-0.812

Buy Seelos Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs, Gold/Commodities
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks, Options, ETFs
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, ETFs
$0 per month

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Seelos Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Seelos Therapeutics under- or over-valued?

Valuing Seelos Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Seelos Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Seelos Therapeutics's P/E ratio

Seelos Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 1x. In other words, Seelos Therapeutics shares trade at around 1x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Seelos Therapeutics financials

Gross profit TTM USD$-10,984,000
Return on assets TTM -82.02%
Return on equity TTM -1489.36%
Profit margin 0%
Book value $0.047
Market capitalisation USD$405.5 million

TTM: trailing 12 months

Shorting Seelos Therapeutics shares

There are currently 2.9 million Seelos Therapeutics shares held short by investors – that's known as Seelos Therapeutics's "short interest". This figure is 16.3% up from 2.5 million last month.

There are a few different ways that this level of interest in shorting Seelos Therapeutics shares can be evaluated.

Seelos Therapeutics's "short interest ratio" (SIR)

Seelos Therapeutics's "short interest ratio" (SIR) is the quantity of Seelos Therapeutics shares currently shorted divided by the average quantity of Seelos Therapeutics shares traded daily (recently around 19.3 million). Seelos Therapeutics's SIR currently stands at 0.15. In other words for every 100,000 Seelos Therapeutics shares traded daily on the market, roughly 150 shares are currently held short.

However Seelos Therapeutics's short interest can also be evaluated against the total number of Seelos Therapeutics shares, or, against the total number of tradable Seelos Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Seelos Therapeutics's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Seelos Therapeutics shares in existence, roughly 40 shares are currently held short) or 0.0414% of the tradable shares (for every 100,000 tradable Seelos Therapeutics shares, roughly 41 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Seelos Therapeutics.

Find out more about how you can short Seelos Therapeutics stock.

Seelos Therapeutics share dividends

We're not expecting Seelos Therapeutics to pay a dividend over the next 12 months.

Have Seelos Therapeutics's shares ever split?

Seelos Therapeutics's shares were split on a 1:30 basis on 23 January 2019. So if you had owned 30 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Seelos Therapeutics shares – just the quantity. However, indirectly, the new 2900% higher share price could have impacted the market appetite for Seelos Therapeutics shares which in turn could have impacted Seelos Therapeutics's share price.

Seelos Therapeutics share price volatility

Over the last 12 months, Seelos Therapeutics's shares have ranged in value from as little as $0.45 up to $6.16. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Seelos Therapeutics's is 3.0052. This would suggest that Seelos Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Seelos Therapeutics overview

Seelos Therapeutics, Inc. , a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel technologies and therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, an anti-alpha-synuclein peptidic inhibitor to treat patients with PD; SLS-008, an orally available antagonist for chemoattractant receptor-homologous molecule for the treatment of chronic inflammation in asthma and pediatric orphan indications; SLS-004 for the treatment of PD; SLS-010, an oral histamine H3A receptor antagonist for narcolepsy and related disorders; and SLS-012, an injectable therapy for post-operative pain management. Seelos Therapeutics, Inc. was founded in 2016 and is headquartered in New York, New York. .

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site